Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: Initial experience

Antonio Orlacchio, Gabriele Bazzocchi, Daniela Pastorelli, Francesca Bolacchi, Mario Angelico, Cristiana Almerighi, Salvatore Masala, Giovanni Simonetti

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The purpose of this study was to retrospectively determine the safety and effectiveness of percutaneous cryoablation, monitored with computed tomography (CT) and ultrasonographic (US) guidance, for the treatment of hepatocellular carcinoma (HCC). Four patients with small HCCs underwent one percutaneous cryoablation treatment session monitored with CT and US guidance. All patients underwent pretreatment blood chemistry testing and imaging evaluation. We treated lesions with simultaneous insertion of multiple 17-G cryoprobes (two or three) and defined technical success when the extension of a visible iceball was beyond 5 mm from the tumor margin. Intralesional enhancement or tumoral size increase was defined as local progression compared with that on images obtained immediately after ablation. We evaluated complications and follow-up (at 1, 3, and 6 months). All patients survived without short- or long-term complications. Cryoablation was technically successful in all patients at the end of the procedure. During follow-up two patients developed disease recurrence. One patient developed local tumor progression on the margin of the lesion; the other, a new HCC. In the case of local tumor progression a new elevation of α-fetoprotein (αFP) levels occurred at first follow-up control. In the other case levels of αFP remained stable during the first 3 months after the procedure, then demonstrated a progressive increase in αFP levels beginning at the fourth month, without tumor evidence during CT control at 3 months. We conclude that percutaneous cryotherapy with US guidance and CT monitoring is a feasible, safe, and effective for treatment of HCC. If local ablative procedures of hepatic lesions are to be performed, percutaneous cryoablation, not laparotomic, should be discussed as an alternative therapeutic measure. Longer follow-up should provide proof of the effectiveness of this technique.

Original languageEnglish
Pages (from-to)587-594
Number of pages8
JournalCardioVascular and Interventional Radiology
Volume31
Issue number3
DOIs
Publication statusPublished - May 2008

Fingerprint

Cryosurgery
Hepatocellular Carcinoma
Tomography
Fetal Proteins
Neoplasms
Cryotherapy
Therapeutics
Safety
Recurrence
Liver

Keywords

  • Cryoablation
  • Hepatocellular carcinoma
  • Interventional procedures
  • Liver

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring : Initial experience. / Orlacchio, Antonio; Bazzocchi, Gabriele; Pastorelli, Daniela; Bolacchi, Francesca; Angelico, Mario; Almerighi, Cristiana; Masala, Salvatore; Simonetti, Giovanni.

In: CardioVascular and Interventional Radiology, Vol. 31, No. 3, 05.2008, p. 587-594.

Research output: Contribution to journalArticle

Orlacchio, Antonio ; Bazzocchi, Gabriele ; Pastorelli, Daniela ; Bolacchi, Francesca ; Angelico, Mario ; Almerighi, Cristiana ; Masala, Salvatore ; Simonetti, Giovanni. / Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring : Initial experience. In: CardioVascular and Interventional Radiology. 2008 ; Vol. 31, No. 3. pp. 587-594.
@article{e882f5a420034879bc98933b26c2249a,
title = "Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: Initial experience",
abstract = "The purpose of this study was to retrospectively determine the safety and effectiveness of percutaneous cryoablation, monitored with computed tomography (CT) and ultrasonographic (US) guidance, for the treatment of hepatocellular carcinoma (HCC). Four patients with small HCCs underwent one percutaneous cryoablation treatment session monitored with CT and US guidance. All patients underwent pretreatment blood chemistry testing and imaging evaluation. We treated lesions with simultaneous insertion of multiple 17-G cryoprobes (two or three) and defined technical success when the extension of a visible iceball was beyond 5 mm from the tumor margin. Intralesional enhancement or tumoral size increase was defined as local progression compared with that on images obtained immediately after ablation. We evaluated complications and follow-up (at 1, 3, and 6 months). All patients survived without short- or long-term complications. Cryoablation was technically successful in all patients at the end of the procedure. During follow-up two patients developed disease recurrence. One patient developed local tumor progression on the margin of the lesion; the other, a new HCC. In the case of local tumor progression a new elevation of α-fetoprotein (αFP) levels occurred at first follow-up control. In the other case levels of αFP remained stable during the first 3 months after the procedure, then demonstrated a progressive increase in αFP levels beginning at the fourth month, without tumor evidence during CT control at 3 months. We conclude that percutaneous cryotherapy with US guidance and CT monitoring is a feasible, safe, and effective for treatment of HCC. If local ablative procedures of hepatic lesions are to be performed, percutaneous cryoablation, not laparotomic, should be discussed as an alternative therapeutic measure. Longer follow-up should provide proof of the effectiveness of this technique.",
keywords = "Cryoablation, Hepatocellular carcinoma, Interventional procedures, Liver",
author = "Antonio Orlacchio and Gabriele Bazzocchi and Daniela Pastorelli and Francesca Bolacchi and Mario Angelico and Cristiana Almerighi and Salvatore Masala and Giovanni Simonetti",
year = "2008",
month = "5",
doi = "10.1007/s00270-008-9293-9",
language = "English",
volume = "31",
pages = "587--594",
journal = "CardioVascular and Interventional Radiology",
issn = "7415-5101",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring

T2 - Initial experience

AU - Orlacchio, Antonio

AU - Bazzocchi, Gabriele

AU - Pastorelli, Daniela

AU - Bolacchi, Francesca

AU - Angelico, Mario

AU - Almerighi, Cristiana

AU - Masala, Salvatore

AU - Simonetti, Giovanni

PY - 2008/5

Y1 - 2008/5

N2 - The purpose of this study was to retrospectively determine the safety and effectiveness of percutaneous cryoablation, monitored with computed tomography (CT) and ultrasonographic (US) guidance, for the treatment of hepatocellular carcinoma (HCC). Four patients with small HCCs underwent one percutaneous cryoablation treatment session monitored with CT and US guidance. All patients underwent pretreatment blood chemistry testing and imaging evaluation. We treated lesions with simultaneous insertion of multiple 17-G cryoprobes (two or three) and defined technical success when the extension of a visible iceball was beyond 5 mm from the tumor margin. Intralesional enhancement or tumoral size increase was defined as local progression compared with that on images obtained immediately after ablation. We evaluated complications and follow-up (at 1, 3, and 6 months). All patients survived without short- or long-term complications. Cryoablation was technically successful in all patients at the end of the procedure. During follow-up two patients developed disease recurrence. One patient developed local tumor progression on the margin of the lesion; the other, a new HCC. In the case of local tumor progression a new elevation of α-fetoprotein (αFP) levels occurred at first follow-up control. In the other case levels of αFP remained stable during the first 3 months after the procedure, then demonstrated a progressive increase in αFP levels beginning at the fourth month, without tumor evidence during CT control at 3 months. We conclude that percutaneous cryotherapy with US guidance and CT monitoring is a feasible, safe, and effective for treatment of HCC. If local ablative procedures of hepatic lesions are to be performed, percutaneous cryoablation, not laparotomic, should be discussed as an alternative therapeutic measure. Longer follow-up should provide proof of the effectiveness of this technique.

AB - The purpose of this study was to retrospectively determine the safety and effectiveness of percutaneous cryoablation, monitored with computed tomography (CT) and ultrasonographic (US) guidance, for the treatment of hepatocellular carcinoma (HCC). Four patients with small HCCs underwent one percutaneous cryoablation treatment session monitored with CT and US guidance. All patients underwent pretreatment blood chemistry testing and imaging evaluation. We treated lesions with simultaneous insertion of multiple 17-G cryoprobes (two or three) and defined technical success when the extension of a visible iceball was beyond 5 mm from the tumor margin. Intralesional enhancement or tumoral size increase was defined as local progression compared with that on images obtained immediately after ablation. We evaluated complications and follow-up (at 1, 3, and 6 months). All patients survived without short- or long-term complications. Cryoablation was technically successful in all patients at the end of the procedure. During follow-up two patients developed disease recurrence. One patient developed local tumor progression on the margin of the lesion; the other, a new HCC. In the case of local tumor progression a new elevation of α-fetoprotein (αFP) levels occurred at first follow-up control. In the other case levels of αFP remained stable during the first 3 months after the procedure, then demonstrated a progressive increase in αFP levels beginning at the fourth month, without tumor evidence during CT control at 3 months. We conclude that percutaneous cryotherapy with US guidance and CT monitoring is a feasible, safe, and effective for treatment of HCC. If local ablative procedures of hepatic lesions are to be performed, percutaneous cryoablation, not laparotomic, should be discussed as an alternative therapeutic measure. Longer follow-up should provide proof of the effectiveness of this technique.

KW - Cryoablation

KW - Hepatocellular carcinoma

KW - Interventional procedures

KW - Liver

UR - http://www.scopus.com/inward/record.url?scp=43249114842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249114842&partnerID=8YFLogxK

U2 - 10.1007/s00270-008-9293-9

DO - 10.1007/s00270-008-9293-9

M3 - Article

C2 - 18236104

AN - SCOPUS:43249114842

VL - 31

SP - 587

EP - 594

JO - CardioVascular and Interventional Radiology

JF - CardioVascular and Interventional Radiology

SN - 7415-5101

IS - 3

ER -